HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.
Saved in:
| Title: | HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer. |
|---|---|
| Authors: | Dieras V; Medical Oncology Department, Centre Eugène Marquis, Rennes, France., Curigliano G; European Institute of Oncology, IRCCS, Milano, Italy.; Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy., Martin M; Medical Oncology Service, Hospital General Universitario Gregorio Marañon, Universidad Complutense, CIBERONC, GEICAM, Madrid, Spain., Lerebours F; Institut Curie, Saint-Cloud, Paris, France., Tsurutani J; The Innovative Center of Translational Research and Clinical Science for Cancer Therapy, Showa Medical University Hospital, Tokyo, Japan., Savard MF; Department of Medicine, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada., Jerzak KJ; Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada., Hu X; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China., Martins de Aquino Pimentel LC; Medical Oncology, Liga Norte-Rio Grandense Contra o Cancer, Natal, Brazil., O'Sullivan CC; Department of Medical Oncology, Mayo Clinic, Rochester, MN., Tokunaga E; Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan., Okines A; Medical Oncology, The Royal Marsden NHS Foundation Trust, London, United Kingdom.; Institute of Cancer Research, London, United Kingdom., Huang CS; Breast Care Center, National Taiwan University Hospital, Taipei, Taiwan., Jacot W; Département d'Oncologie Médicale, Institut Regional du Cancer de Montpellier, Montpellier University, INSERM U1194, Montpellier, France., Sohn J; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea., Cronemberger Silva E; Medical Oncology, Centro Regional Integrado de Oncologia (CRIO), Fortaleza, Brazil., Mueller V; Department of Gynecology and University Breast Center, Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany., Yang S; Biostatistics, Pfizer Inc, Bothell, WA., Granata G; Oncology Late Stage Development, Pfizer AG, Zug, Switzerland., Shen Q; Oncology, Research and Development, Pfizer Inc, Collegeville, PA., Santarpia L; Oncology, Research and Development, Pfizer AG, Zug, Switzerland., Hamilton E; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN. |
| Corporate Authors: | HER2CLIMB-05 Investigators |
| Source: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2026 Jun 10; Vol. 44 (17), pp. 1597-1607. Date of Electronic Publication: 2025 Dec 10. |
| Publication Type: | Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
